The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer
Open accessAbstract
Combined targeting of KRAS-G12C, mTOR, and IGF1R enhances and extends the response to recently developed KRAS-G12C inhibitors in lung cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Still, in all cases, combination therapies to suppress adaptive feedback proved key to optimizing the frequency and durability of response in each tumor type (34,50,51).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [51]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other combinatorial partners including PI3K, mTOR, and Aurora Kinase inhibitors have been shown to have higher efficacy than EGFR inhibition in combination with KRAS G12C inhibition in lung cancer(10, 12, 13).”
From EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer. (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, the restoration of flux through the ERK pathway was similarly observed after ARS-1620 treatment, and the feedback activation of Ras upstream RTKs has been raised as one of the key mechanisms of resistance to ARS-1620.12,15”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [15]
In the citing paper
“These experiments have identified receptor tyrosine kinase (RTK) signaling to PI3K and mTOR (23, 37–40), as well as the autophagy pathway (30) as collateral dependencies with KRAS and MAPK pathway inhibitors.”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature reviews. Cancer · doi:10.1038/nrc969 · Cited by 3,354
Self-citationThe Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., & Sabatini, D. M. (2008) · Science · doi:10.1126/science.1157535 · Cited by 2,773
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Bollag, G. E., Hirth, P., Tsai, J. Y., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W. R., Zhang, C., Zhang, Y., Habets, G. G. M., et al. (2010) · Nature · doi:10.1038/nature09454 · Cited by 1,875
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Carracedo, A., Ma, L., Teruya-Feldstein, J., Rojo, F., Salmena, L., Alimonti, A., Egia, A., Sasaki, A. T., Thomas, G., Kozma, S. C., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34739 · Cited by 1,381
Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · cited 5×
“To avoid toxicities associated with the presence of a MEK inhibitor in this triple combination, we substituted a KRAS-G12C inhibitor, ARS-1620 (20), for the MEK inhibitor.”
BackgroundMethodInfluentialSelf-citation
Cited by
Sorted by citations
Items 101–200 of 203
Yang, Y., Mei, H., Han, X., Zhang, X., Cheng, J., Zhang, Z., Wang, H., & Xu, H. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00508-y · Cited by 17
Zhang, Y., Liu, L., Pei, J., Ren, Z., Deng, Y., & Yu, K. (2024) · Oncogene · doi:10.1038/s41388-023-02924-y · Cited by 16
Yang, H., Niu, S., Guo, M.-H., & Xue, Y. (2024) · Archives of Toxicology · doi:10.1007/s00204-024-03777-4 · Cited by 18
KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies
Naim, N., Moukheiber, S., Daou, S., & Kourié, H. R. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103524 · Cited by 16
iRhom2 regulates ERBB signalling to promote KRAS-driven tumour growth of lung cancer cells
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2022) · Journal of Cell Science · doi:10.1242/jcs.259949 · Cited by 16
The Research Progress of Direct KRAS G12C Mutation Inhibitors
Yang, A., Li, M., & Fang, M. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.631095 · Cited by 15
“Miriam et al [16] found that deletion of MTOR genes can make cells significantly sensitive to KRAS and IGF1R inhibitors.”
BackgroundCovalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2
Klebba, J. E., Roy, N., Bernard, S. M., Grabow, S., Hoffman, M. A., Miao, H., Tamiya, J., Wang, J., Berry, C., Esparza-Oros, A., et al. (2025) · Science · doi:10.1126/science.adv2684 · Cited by 15
Self-citationDewan, A., Tattoli, I., & Mascellino, M. T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146958 · Cited by 16
RetractedSakamoto, K., Qi, Y., & Miyako, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-27825-8 · Cited by 14
TTI1 promotes non‐small‐cell lung cancer progression by regulating the mTOR signaling pathway
Zhang, L., Yang, X., Wu, Z., Liao, Z., Wang, D., Chen, S., Lü, F., Wu, Y., & Zhu, S. (2022) · Cancer Science · doi:10.1111/cas.15668 · Cited by 14
Sayama, H., Marcantonio, D. H., Nagashima, T., Shimazaki, M., Minematsu, T., Apgar, J. F., Burke, J. M., Wille, L., Nagasaka, Y., & Kirouac, D. C. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12661 · Cited by 13
Bontoux, C., Hofman, V., Brest, P., Ilié, M., Mograbi, B., & Hofman, P. M. (2022) · Cancers · doi:10.3390/cancers14071628 · Cited by 17
New insights into the interaction of the immune system with non-small cell lung carcinomas
Hofman, P. M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-178 · Cited by 16
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
Foote, J. B., Mattox, T. E., Keeton, A. B., Chen, X., Smith, F., Berry, K. L., Holmes, T., Wang, J., Huang, C.-H., Ward, A. B., et al. (2023) · doi:10.1101/2023.05.17.541233 · Cited by 13
Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy
Tatlı, Ö., & Doğanay, G. D. (2021) · Molecules · doi:10.3390/molecules26247561 · Cited by 14
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Reshkin, S. J., Cardone, R. A., & Koltai, T. (2024) · Cells · doi:10.3390/cells13070602 · Cited by 14
CD47-mediated immune evasion in early-stage lung cancer progression
Chuang, C., Zhen, Y., Ma, J.-Y., Lee, T.-H., Hung, H.-Y., Wu, C.-C., Wang, P., Huang, C.-T., Huang, M.-S., Hsiao, M., et al. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150066 · Cited by 15
Mesoporous silica nanoparticles: a versatile carrier platform in lung cancer management
Dhingra, S., Goyal, S., Thirumal, D., Sharma, P. M., Kaur, G., & Mittal, N. (2024) · Nanomedicine · doi:10.1080/17435889.2024.2348438 · Cited by 13
Parry, C., Pellicano, F., Schüttelkopf, A. W., Beyer, K. S., Bower, J. F., Bryson, A., Cameron, K., Cerutti, N. M., Clark, J. P., Davidson, S. C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02929 · Cited by 12
Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis
Murugesan, S., Jayakumar, M., Seedevi, P., Sivasankar, P., Murugan, T., Siddiqui, S. S., & Loganathan, S. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666201009130008 · Cited by 14
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
Synthetic Vulnerabilities in the KRAS Pathway
Román, M., Hwang, E. E., & Sweet-Cordero, A. (2022) · Cancers · doi:10.3390/cancers14122837 · Cited by 14
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
Patel, A., & Gulhati, P. (2024) · Cancers · doi:10.3390/cancers16081551 · Cited by 12
Li, W., Lyu, Y., Wang, S., Zhou, X., Ma, J., Xu, C., Li, F., Ying, J., Guo, L., Qiu, T., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100163 · Cited by 12
Henkels, K. M., Rehl, K. M., & Cho, K. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.673096 · Cited by 11
Hofman, P. M. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020015 · Cited by 12
Wang, P., Pan, X., Feng, Q., Zou, H., Cui, J., He, Y., Luo, Y., & Yang, J.-L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0222 · Cited by 11
Open Structural Data in Precision Medicine
Nussinov, R., Jang, H., Nir, G., Tsai, C., & Cheng, F. (2022) · Annual Review of Biomedical Data Science · doi:10.1146/annurev-biodatasci-122220-012951 · Cited by 12
Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models
Sisler, D. J., Hinz, T. K., Le, A. T., Kleczko, E. K., Nemenoff, R. A., & Heasley, L. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1094123 · Cited by 11
Future perspectives from lung cancer pre-clinical models: new treatments are coming?
Bersani, F., Morena, D., Picca, F., Morotti, A., Tabbò, F., Bironzo, P., Righi, L., & Taulli, R. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-189 · Cited by 10
McGuire, A., McConechy, M. K., Melosky, B. L., English, J. C., Choi, J. J., Peng, D., Yee, J., Furman, B. L. S., Hernandez, R. A., Feijão, P., et al. (2022) · Current Oncology · doi:10.3390/curroncol29040215 · Cited by 11
Colombino, M., Palomba, G., Casula, M., Pisano, M., Tore, S., Serra, R., Putzu, C., Fadda, G. M., Maestrale, G. B., Casula, S., et al. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104925 · Cited by 10
Weak links: Advancing target‐based drug discovery by identifying the most vulnerable targets
Bosch, B., DeJesus, M. A., Schnappinger, D., & Rock, J. M. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15139 · Cited by 9
Wang, X., Breuer, J., Garbe, S., Giordano, F. A., Brossart, P., Feldmann, G., & Bisht, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116249 · Cited by 10
IGF-1R Inhibitors in Cancer: A Review of Available Evidence and Future Outlook
Guven, D., Ahmed, J., Stephen, B., & Naing, A. (2025) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2025.104809 · Cited by 10
Drug–drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers
Fujita, H., Arai, S., Arakawa, H., Hamamoto, K., Kato, T., Arai, T., Nitta, N., Hotta, K., Hosokawa, N., Ohbayashi, T., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117674 · Cited by 8
KRAS G12C inhibition and innate immune targeting
Tani, T., Kitajima, S., Conway, E. B., Knelson, E. H., & Barbie, D. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1902991 · Cited by 9
Fong, Z., & Lee, W.-L. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0332 · Cited by 9
Yu, J. X., Suh, J. M., Popova, K. D., Garcia, K., Joshi, T. V., Culbertson, B., Spinelli, J. B., Subramanyam, V., Lou, K., Charbonneau, T., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01130-5 · Cited by 8
KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
Gelfer, R., Gulla, A., Kalvin, H. L., Song, Y., Harding, J. J., Abou‐Alfa, G. K., O'Reilly, E. M., Park, W., Chandwani, R., Wei, A. C.-C., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00263 · Cited by 9
Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 7
Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
Endres, N., Do, S., Mroue, R. M., Terrett, J. A., Saabye, M., Oh, A., Hunsaker, T., Chan, E., (1471192), J. C. T., Nguyen, L. K., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02272 · Cited by 8
If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer
Köhler, J., & Janne, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063025 · Cited by 7
Salmani-Javan, E., Jadid, M. F. S., & Zarghami, N. (2024) · PubMed Central · doi:10.22038/ijbms.2023.72407.15749 · Cited by 8
Liu, Y., Wu, L., Lü, H., Wu, E., Ni, J., & Zhou, X. (2021) · Journal of Oncology · doi:10.1155/2021/2721466 · Cited by 7
Mohapatra, T., & Dixit, M. (2022) · ACS Omega · doi:10.1021/acsomega.2c05505 · Cited by 6
Prajapati, V., Singh, A. K., Kumar, A. M., Singh, H., Pathak, P., Grishina, M., Kumar, V., Khalilullah, H., Verma, A., & Kumar, P. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00923a · Cited by 6
Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway
Hao, M.-W., Zhang, T., Dong, D. F., Xin Min, Z. H. O. U., & Gao, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-02683-8 · Cited by 6
Ito, M., Miyata, Y., Hirano, S., Morihara, N., Takemoto, M., Irisuna, F., Kushitani, K., Suda, K., Soh, J., Takeshima, Y., et al. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02187-y · Cited by 6
Liu, S., Jiang, Y., Fu, Y., Wang, S., Fu, R., Gao, M., Zhao, Y., Chen, S., Yang, Y., Yang, W., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012886 · Cited by 6
Ras Family of Small GTPases in CRC: New Perspectives for Overcoming Drug Resistance
Río-Vilariño, A., del Puerto‐Nevado, L., García‐Foncillas, J., & Cebrián, A. (2021) · Cancers · doi:10.3390/cancers13153757 · Cited by 6
Combinatorial approaches for mitigating resistance to KRAS-targeted therapies
Warren, H. R., Ross, S. J., Smith, P. D., Coulson, J. M., & Prior, I. A. (2022) · Biochemical Journal · doi:10.1042/bcj20220440 · Cited by 6
Li, R., Huang, X., Wang, R., Ren, Z., Zhu, Y. L., Lu, T., Sun, Y., & Hao, C. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117718 · Cited by 6
Huang, R., Gong, X., Du, J., Xu, G., Qian, J., Liao, G., Lin, Y., Pan, M., Zheng, B., Yuan, W., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704347 · Cited by 6
Liu, J., Zheng, Y., Gao, Y., Quan, Z., Qiao, B., Luo, L., Li, T., Duan, L., Yang, J., Luo, C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00075 · Cited by 5
RetractedUnderstanding and drugging RAS: 40 years to break the tip of the iceberg
Brady, D. C., Hmeljak, J., & Dar, A. C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049519 · Cited by 5
Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the MousePreprint
Vaishnavi, A., Kinsey, C. G., & McMahon, M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041385 · Cited by 5
Targeting Mutant KRAS for Immunogenic Cell Death Induction
Galluzzi, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.11.004 · Cited by 4
Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasisPreprint
Tomić, G., Sheridan, C., Refermat, A. Y., Baggelaar, M. P., Sipthorp, J., Sudarshan, B., Ocasio, C. A., Suárez‐Bonnet, A., Priestnall, S. L., Herbert, E., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.08.527637 · Cited by 4
Self-citationKRAS mutations in colorectal cancer: impacts on tumor microenvironment and therapeutic implications
Emami, A., Sharif, P. M., & Rezaei, N. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2500426 · Cited by 3
Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer
Vincent, T., Sakthivel, K. M., Josephine, C. M. R., Prasad, R., Kathirvelan, C., Kumar, P., Saravanan, M., & Rasmi, R. R. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152204 · Cited by 3
Targeting K-Ras Mutations Show Promise Towards Ending Ras’s “Undruggable” Era
Adams, P. D., & Muhoza, D. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666221003124202 · Cited by 3
143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models
Xu, L., Zheng, S.-X., Mei, L., Yang, K., Wang, Y., Zhou, Q., Kong, X., Zheng, M.-Y., Jiang, H., & Xie, C. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01053-2 · Cited by 4
Yang, W., Ge, J., Yuan, M., Li, J., Pan, L., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001428 · Cited by 3
Identifying genes associated with resistance to KRAS G12C inhibitors via machine learning methods
Lin, X., Ma, Q., Chen, L., Guo, W., Huang, Z., Huang, T., & Cai, Y. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130484 · Cited by 3
Drugging the undruggable: Advances in targeting KRAS signaling in solid tumors
Tripathi, P., Kumari, R., & Pathak, R. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2023.11.004 · Cited by 3
Choi, J., Hyun, J., Hyun, J., Kim, J.-H., Lee, J. H., & Bang, D. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01164-8 · Cited by 5
Orthotopically Implanted Murine Lung Adenocarcinoma Cell Lines for Preclinical Investigations
Kalyanaraman, K. J., Corey, Z., Navarro, A., Heasley, L. E., & Nemenoff, R. A. (2025) · Cancers · doi:10.3390/cancers17152424 · Cited by 2
Yang, J., Li, Y., Ma, B., Xie, H., Chen, L., Gao, X., & He, W. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1675 · Cited by 1
Tao, X., Gao, Q., Chen, Y., Cai, N., & Hao, C. (2025) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02360-1 · Cited by 2
Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway
Kim, N., Shin, I., Kim, Y., Jeon, E., Lee, J., Lee, C., Nam, Y., Lee, S., Ju, E., Kim, C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.768022 · Cited by 2
KRAS G12C as a Target of Naringenin for Inducing Cell Death in NCI-H23 Cells
Patar, A. K., Kma, L., Barman, J., Ghosh, S., & Baruah, T. J. (2022) · Pharmacognosy Research · doi:10.5530/pres.14.3.37 · Cited by 2
Hilzenrat, R. A., Yip, S. S. F., Melosky, B. L., Ho, C., Laskin, J. J., Sun, S. B., Choi, J. J., & McGuire, A. (2022) · Current Oncology · doi:10.3390/curroncol30010012 · Cited by 2
Targeted Therapies for Pancreatic Cancer
Lee, M. S., & Pant, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-38623-7_5 · Cited by 2
Mandell, J. D., Diviti, S., Xu, M. L., & Townsend, J. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126589 · Cited by 1
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241264853 · Cited by 1
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics
Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.009 · Cited by 1
Imaging mass cytometry in preclinical studies of lung cancer
van Maldegem, F. (2024) · Elsevier eBooks · doi:10.1016/b978-0-12-822213-3.00004-8 · Cited by 1
KRAS combination strategies: How well aligned is clinical and preclinical research?
Nadal, E., Ambrogio, C., Santamarı́a, D., & Lindsay, C. R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00018-8 · Cited by 2
Kobayashi, K., Terai, H., Yasuda, H., Hamamoto, J., Hayashi, Y., Takeuchi, O., Mitsuishi, Y., Masuzawa, K., Manabe, T., Ikemura, S., et al. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.11.110 · Cited by 1
Palmitoyl transferase ZDHHC20 promotes pancreatic cancer metastasisPreprint
Tomić, G., Sheridan, C., Refermat, A. Y., Baggelaar, M. P., Sipthorp, J., Sudarshan, B., Ocasio, C. A., Suárez‐Bonnet, A., Priestnall, S. L., Herbert, E., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2648300/v1 · Cited by 1
Self-citationShifting KRAS hotspot mutations inhibition paradigm in colorectal cancerPreprint
Brás, A. R., Lopes, A., Mendes, N. M., Costa, P. J., Ferreira, A. I., Granja, S., da Silva, A. P. M., Tortosa, F., Baltazar, F., Gärtner, F., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552513 · Cited by 1
Mitsiades, C. S. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034900
iRhom2 regulates ERBB signalling to promote KRAS-driven oncogenesisPreprint
Sieber, B., Lu, F., Stribbling, S. M., Grieve, A. G., Ryan, A. J., & Freeman, M. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.06.455383
Improving cancer therapy through unconventional strategies
Neto, J. M. F. (2021) · Utrecht University Repository (Utrecht University) · doi:10.33540/1009
Lung Adenocarcinoma: Next Generation Sequencing and Outcome in Regional Community Oncology Setting
Skacel, L., Babcock, M. J., Harb, A. J., Curtis, A. D., Liou, C. L., Brawn, K., Sandor, F., & Skacel, M. (2021) · Journal of Surgery and Research · doi:10.26502/jsr.10020194
Ge, J., Yuan, M., Lin, J., Ren, J., Dou, G., Yang, L., Zhou, Y., Xie, H., Wang, X., & Zhong, S. (2022) · Research Square · doi:10.21203/rs.3.rs-1391554/v1
Shu, C., Cui, J., Chen, J., Zhang, Y., Ren, Y., Li, J., Chen, D., Ding, K., Li, A., Zhang, R., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1690983/v1
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850.v1
Data from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
Ryan, M. B., de la Cruz, F. F., Phat, S., Myers, D. T., Wong, E., Shahzade, H. A., Hong, C. B., & Corcoran, R. B. (2023) · doi:10.1158/1078-0432.c.6529850
Alhousami, T., Diny, M., Ali, F., Shin, J., Kumar, G., Kumar, V., Campbell, J. D., Noonan, V. L., Hanna, G. J., Denis, G. V., et al. (2023) · doi:10.1158/1541-7786.c.6545655
Alhousami, T., Diny, M., Ali, F., Shin, J., Kumar, G., Kumar, V., Campbell, J. D., Noonan, V. L., Hanna, G. J., Denis, G. V., et al. (2023) · doi:10.1158/1541-7786.c.6545655.v1
Khan, H. Y., Nagasaka, M., Li, Y., Aboukameel, A., Uddin, M. H., Sexton, R. E., Bannoura, S. F., Mzannar, Y., Hallak, M. N. A., Kim, S. H., et al. (2023) · doi:10.1158/2767-9764.c.6550541
Conclusions: the future of RAS drug discovery
Gill, A. L., & Shokat, K. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-21861-3.00009-7
Pardo, L., Moore, M., Deshmukh, R. S., Powley, I. R., Waldron, J. A., Kruspig, B., McGarry, L., Wood, C. S., Leslie, H., Hughes, M. M., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.19.644135
Jiao, D., Chen, Y., Liu, X., Xu, W., Tang, X., Chen, J., Yan, L., & Chen, Q. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04067-w
Trécesson, S. D. C., East, P., Pillsbury, C. E., dos Santos, M. S., Cha, H., Colliver, E., Gilmore, T., Rana, S., Moore, C., Lighterness, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.25.690426
Self-citationMAPK pathway modulation and its implications in KRAS mutant lung adenocarcinoma
Román, S. D. H. (2023) · theses.fr (ABES) · doi:10.70675/8eaccae1ze96bz4279zb69fzaafa5e50c341
Metadata
- Authors
- Molina-Arcas, M., Moore, C., Rana, S., van Maldegem, F., Mugarza, E., Romero-Clavijo, P., Herbert, E., Horswell, S., Li, L.-S., Janes, M. R., Hancock, D. C., & Downward, J.
- Affiliations
- Oncogene Biology, Francis Crick Institute, London NW1 1AT, UK.
- The Francis Crick Institute (GB)
- Institute of Cancer Research (GB)
- Royal Veterinary College (GB)
- Wellspring Biosciences (United States) (US)
- Corresponding author
- Downward, Julian
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2019-09-18
- Volume
- 11
- Issue
- 510
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6764843
- OpenAlex
- W2973796265
- Semantic Scholar
- dca6223aaab20972c7583a0426e8b63dfc81d7f3
- Cited by
- 203
- References
- 55
- Citations by year
- 2026: 8 · 2025: 22 · 2024: 27 · 2023: 32 · 2022: 36 · 2021: 51 · 2020: 24 · 2019: 3
- FWCI
- 20.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RVC Research Online (Royal Veterinary College) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Wellcome (103799/Z/14/Z, FC001070)
- H2020 European Research Council (RASTARGET)
- Medical Research Council (FC001070)
- Cancer Research UK (FC001070)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS G12C inhibitors, KRAS-mutant lung cancer, lung adenocarcinoma, combination therapy, MEK inhibition, IGF1R inhibition, mTOR inhibition, MAPK signaling, IGF1R signaling, tumor regression, mouse model
- MeSH terms
- Animals, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cell Survival, Imidazoles, Lung Neoplasms, Mice, Nude, Mutation, Pyrazines, Pyridones, Pyrimidinones, Signal Transduction, Proto-Oncogene Proteins p21(ras), Receptor, IGF Type 1, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinase Kinases, RNA, Small Interfering, Protein Kinase Inhibitors, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
